CANbridge Pharma Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
39
- Stock Symbol
-
01228
- Share Price
-
$0.21
- (As of Thursday Closing)
CANbridge Pharma General Information
Description
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
Contact Information
Website
www.canbridgepharma.comCorporate Office
- Room 3301, 29th Floor, Building A
- Number 2 Zhongguancun South Street, Haidian District
- Beijing, Jiangsu 100086
- China
Corporate Office
- Room 3301, 29th Floor, Building A
- Number 2 Zhongguancun South Street, Haidian District
- Beijing, Jiangsu 100086
- China
CANbridge Pharma Timeline
CANbridge Pharma Stock Performance
As of 19-Nov-2026, CANbridge Pharma’s stock price is $0.21. Its current market cap is $126M with 597M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.21 | $0.22 | $0.18 - $0.45 | $126M | 597M | 551K | -$0.03 |
CANbridge Pharma Financials Summary
As of 30-Jun-2026, CANbridge Pharma has a trailing 12-month revenue of $7.96M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 168,834 | 142,839 | 22,965 | 37,290 |
| Revenue | 7,957 | 6,950 | 11,860 | 14,540 |
| EBITDA | (10,066) | 4,008 | (56,762) | (49,811) |
| Net Income | (11,649) | 2,061 | (61,685) | (53,547) |
| Total Assets | 28,315 | 23,638 | 16,002 | 55,774 |
| Total Debt | 4,240 | 2,299 | 18,599 | 20,022 |
CANbridge Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CANbridge Pharma Comparisons
Industry
Financing
Details
CANbridge Pharma Competitors (60)
One of CANbridge Pharma’s 60 competitors is Inhibrx, a Formerly VC-backed company based in La Jolla, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inhibrx | Formerly VC-backed | La Jolla, CA | ||||
| Calliditas Therapeutics France | Corporate Backed or Acquired | Saint-Julien- en-Genevois, France | ||||
| ADC Therapeutics | Formerly VC-backed | Epalinges, Switzerland | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China |
CANbridge Pharma Patents
CANbridge Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025261418-A1 | Dystrophin constructs and methods of use thereof | Pending | 26-Apr-2024 | ||
| WO-2025227131-A1 | Dystrophin constructs and methods of use thereof | Pending | 26-Apr-2024 | ||
| WO-2023028567-A2 | Aav particles comprising a liver-tropic capsid protein and acid alpha-glucosidase (gaa) and their use to treat pompe disease | Inactive | 25-Aug-2021 | ||
| AU-2022332298-A1 | Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease | Inactive | 25-Aug-2021 | ||
| CA-3229998-A1 | Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease | Pending | 25-Aug-2021 | A61K48/0058 |
CANbridge Pharma Signals
CANbridge Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CANbridge Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
CANbridge Pharma FAQs
-
When was CANbridge Pharma founded?
CANbridge Pharma was founded in 2012.
-
Where is CANbridge Pharma headquartered?
CANbridge Pharma is headquartered in Beijing, China.
-
What is the size of CANbridge Pharma?
CANbridge Pharma has 39 total employees.
-
What industry is CANbridge Pharma in?
CANbridge Pharma’s primary industry is Pharmaceuticals.
-
Is CANbridge Pharma a private or public company?
CANbridge Pharma is a Public company.
-
What is CANbridge Pharma’s stock symbol?
The ticker symbol for CANbridge Pharma is 01228.
-
What is the current stock price of CANbridge Pharma?
As of 19-Nov-2026 the stock price of CANbridge Pharma is $0.21.
-
What is the current market cap of CANbridge Pharma?
The current market capitalization of CANbridge Pharma is $126M.
-
What is CANbridge Pharma’s current revenue?
The trailing twelve month revenue for CANbridge Pharma is $7.96M.
-
Who are CANbridge Pharma’s competitors?
Inhibrx, Calliditas Therapeutics France, ADC Therapeutics, Alnylam Pharmaceuticals, and BeOne Medicines are some of the 60 competitors of CANbridge Pharma.
-
What is CANbridge Pharma’s annual earnings per share (EPS)?
CANbridge Pharma’s EPS for 12 months was -$0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process